| 000 | 01572 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513191513.0 | ||
| 264 | 0 | _c19990907 | |
| 008 | 199909s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/S0140-6736(98)05447-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aThomas, S R | |
| 245 | 0 | 0 |
_aPulmonary disease severity in men with deltaF508 cystic fibrosis and residual chloride secretion. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cMar 1999 |
||
| 300 |
_a984-5 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 |
_aAdenosine Triphosphate _xpharmacology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAmiloride _xpharmacology |
| 650 | 0 | 4 |
_aBronchodilator Agents _xpharmacology |
| 650 | 0 | 4 |
_aChloride Channels _xdrug effects |
| 650 | 0 | 4 |
_aChlorides _xmetabolism |
| 650 | 0 | 4 |
_aCystic Fibrosis _xgenetics |
| 650 | 0 | 4 |
_aCystic Fibrosis Transmembrane Conductance Regulator _xgenetics |
| 650 | 0 | 4 |
_aDiuretics _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aForced Expiratory Volume _xdrug effects |
| 650 | 0 | 4 | _aHomozygote |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoproterenol _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMembrane Potentials _xdrug effects |
| 650 | 0 | 4 |
_aMutation _xgenetics |
| 650 | 0 | 4 | _aRetrospective Studies |
| 700 | 1 | _aJaffe, A | |
| 700 | 1 | _aGeddes, D M | |
| 700 | 1 | _aHodson, M E | |
| 700 | 1 | _aAlton, E W | |
| 773 | 0 |
_tLancet (London, England) _gvol. 353 _gno. 9157 _gp. 984-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(98)05447-6 _zAvailable from publisher's website |
| 999 |
_c10417522 _d10417522 |
||